Seong-Jin Kim
Fortune : 6 M $ au 31/08/2026
Fortune : 6 M $ au 31/08/2026
Seong-Jin Kim is the founder of MedPacto, Inc. (2013) as Chief Executive Officer, Director & CTO.
Dr. Kim is the founder of Celloram, Inc. (2018) as Director.
Dr. Kim is currently the Head-Cancer Institute at CHA University.
Formerly, Dr. Kim served as Independent Director, Head-Research & Development at THERAGEN ETEX Co., Ltd. Education includes a doctorate from the University of Tsukuba.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MEDPACTO, INC. 6,36 % | 30/06/2026 | 2 181 216 ( 6,36 % ) | 4 M $ | 31/08/2026 |
THERAGEN ETEX CO., LTD 2,85 % | 15/03/2025 | 1 059 025 ( 2,85 % ) | 2 M $ | 31/08/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| MEDPACTO, INC. | Directeur Général | 19/06/2013 |
CHA University
CHA University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/07/2011 |
Celloram, Inc.
Celloram, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies to fight against cancer and metabolic disorders | Fondateur | 01/01/2018 |
| Sociétés | Poste | Fin |
|---|---|---|
| THERAGEN ETEX CO.,LTD. | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
University of Tsukuba
University of Tsukuba Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
THERAGEN ETEX Co., Ltd.
THERAGEN ETEX Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
CHA University
CHA University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MedPacto, Inc.
MedPacto, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops anti-cancer drugs | Health Technology |
Celloram, Inc.
Celloram, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies to fight against cancer and metabolic disorders | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national